Destiny Pharma Result of Annual General Meeting
/in Destiny PharmaLink to Full Article Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed. The full text of each resolution was included […]
Destiny Pharma Notice to Register for 2021 AGM
/in Destiny PharmaLink to Full Article Brighton, United Kingdom – 19 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, as announced on 4 May 2021, will hold its 2021 Annual General Meeting (“AGM”) at the offices of finnCap Ltd, Destiny Pharma’s Nominated Advisor and […]
Destiny Pharma – Posting of Annual Report and Notice of AGM
/in Destiny PharmaLink to Full Article Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 4 May 2021 – Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that the following documents are now available on the Company’s website at www.destinypharma.com […]
Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel
/in Destiny PharmaLink to Full Article Destiny Pharma Reports Positive Phase 2b Results for XF-73 Nasal Gel Primary endpoint achieved with >99% nasal bacterial load reduction (p<0.0001) Excellent safety profile. No treatment related adverse events Brighton, United Kingdom – 29th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of novel […]
Destiny Pharma Notice of Full Year Results and Clinical Trial Update
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Notice of Full Year Results and Clinical Trial Update Brighton, United Kingdom – 16th March 2021 – Destiny Pharma (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its financial results for […]
Destiny Pharma Announces Agreement with NIAID
/in Destiny PharmaDestiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Agreement with NIAID to Evaluate a Novel XF-73 Formulation in Skin Wound Infection Brighton, United Kingdom, 15 March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces […]
Destiny Pharma CSO Joins UKRI COVID-19 Taskforce
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Chief Scientific Officer Dr Bill Love Joins UKRI COVID-19 Research and Innovation Taskforce Brighton, United Kingdom – 10th March 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can […]
Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Brazilian Patent Granted for XF-73 nasal gel preventing post-surgical infections Brighton, United Kingdom – 3rd February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening […]
Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board
/in Destiny PharmaLink to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]